Windham Venture Partners

Windham Venture Partners

Windham Venture Partners is a New York City based venture capital firm investing in healthcare companies with a focus on medical technology and digital health.

Windham Venture Partners is a New York City, New York based venture capital firm. They invest in healthcare companies, with an emphasis on medical technology and digital health.

When they invest, they look for a company to have an experienced and knowledgeable leadership team, an evidence-based technology or procedure which approaches a problem in a new or superior way without intellectual property barriers and a concept past development stage, addressing a large market with impressive data and a clear value proposition.

Investment

Windham Venture Partners has made investments in NovellusDx, MC10, Nebula Genomics, Earlens Corporation, Nuvaira, NeuSpera Medical, CVRx, CredSimple, SubjectWell, Science Exchange, Blueprint Health, Cartiva, Coravin and Cureatr.

Windham Venture Partners has exited investments in Transactis, Neotract and Cartiva.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Nebula Genomics

Nebula Genomics is a genetics company developing a platform for individuals to get their personal genome sequenced, and then enable them to store and control that information through cryptographic encryption on the blockchain.

A technology company offering research and development services focused on cardiovascular disease.

Personal Genome Diagnostics is a Baltimore-based molecular diagnostics company developing genomic testing and diagnostic kits.

NovellusDx is an Israel-based biotechnology company developing live-cell based assays to monitor signalling pathways.

Neuspera Medical is a San Jose, California-based medical device company.

Earlens Corporation is a Menlo Park, California-based company.

Nuvaira, Inc. is a Minneapolis-based medical device company.

Subjectwell is an Austin, Texas-based company in the pharmaceuticals industry founded in 2012.

10 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Adam E. Fine

General Partner & CEO

Joseph Proto

Venture Partner

Lorne Taichman, MD, PhD

Director, Science & Technology

Luke Hartstein

Associate

Matthew Whitman

Principal

Raquel Babio

Operations Associate

Roger S. Fine

General Partner & Chairman

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.